 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Depomed, Inc. (DEPO) is a specialty pharmaceutical company.
The firm develops products for pain and other central nervous system conditions in the United States.
It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults.
The company is involved in the clinical development of IW-3718 refractory gastroesophageal reflux disease program using Acuform drug delivery technology. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies.
The company also has a portfolio of royalty and milestone producing license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc.
Shares have formed a bullish "cup & handle" and higher share prices are expected for this stock.
52-Weeks Trading Range: $9.85 - $25.54
Entry Point: $24.85
Stop Loss: $23.60
Target: $27.40
DEPO fell below our stop loss. Closed at $22.70.
